ライフサイエンスコーパス: platelet-activating factor receptor

1 holine residues on pneumococcal cell wall to platelet-activating factor receptor.

2 lin receptor, or cell wall phosphorylcholine/platelet-activating factor receptor.

3 signaling can be augmented via the epidermal platelet-activating factor receptor.

4 or-negative epithelial cell line KB with the platelet-activating factor receptor.

5 nthesized platelet-activating factor and the platelet-activating factor receptor agonist 1-palmitoyl-

6 oupled receptors and excluded key candidates platelet-activating factor receptor and CCR5.

7 experiments revealed that L5 signals through platelet-activating factor receptor and lectin-like oxid

8 s demonstrate the differential expression of platelet-activating factor receptor and TLR-4 in uterine

9 B versus 1 microM in KB cells expressing the platelet-activating factor receptors) and increased the

10 d receptor-1, protease activated receptor-3, platelet activating factor receptor, and factor V.

11 ine, an H1R antagonist, blocked EAE, and the platelet activating factor receptor antagonist CV6209 re

12 ventricular injection with the intracellular platelet-activating factor receptor antagonist BN 50730

13 rom the international phase III trial of the platelet-activating factor receptor-antagonist Lexipafan

14 nti-eotaxin and anti-RANTES mAbs, but not by platelet-activating factor receptor antagonists (CV6209,

15 ted by pretreatment with the two competitive platelet-activating factor receptor antagonists CV-6209

16 s NK(2), calcitonin gene-related peptide, or platelet-activating factor receptor antagonists had no e

17 Pretreatment of HaCaT cells with platelet-activating factor receptor antagonists, or over

18 Platelet-activating factor receptor blockade protected s

19 tion was assessed, and whether the epidermal platelet-activating factor receptor could augment toxin-

20 f oxidative stress-induced signaling seen in platelet-activating factor receptor-expressing cells was

21 ctive effect resulted in part from decreased platelet-activating factor receptor expression on endoth

22 antibody or therapeutic agents that modulate platelet-activating factor receptor expression, may conf

23 D synthase, histamine receptor type 1 (H1R), platelet activating factor receptor, Ig Fc epsilon recep

24 stry studies demonstrate the presence of the platelet-activating factor receptor in both endometrial

25 Expression of the platelet-activating factor receptor in KB cells lowered

26 studies suggest involvement of the epidermal platelet-activating factor receptors in oxidant-mediated

27 milar involvement for an unrelated GPCR (the platelet-activating factor receptor), indicating that it

28 nally, retroviral-mediated expression of the platelet-activating factor receptor into the platelet-ac

29 let-activating factor and express functional platelet-activating factor receptors linked to calcium m

30 platelet-activating factor receptor into the platelet-activating factor receptor-negative epithelial

31 d by retroviral-mediated transduction of the platelet-activating factor receptor-negative epithelial

32 creased adherence mediated by binding to the platelet activating factor receptor on epithelial cells.

33 Anaphylaxis was inhibited by platelet-activating factor receptor or histamine recepto

34 eir ability to generate oxidized lipids with platelet-activating factor receptor (PAF-R) agonist acti

35 by generating oxidized lipid agonists of the platelet-activating factor receptor (PAF-R).

36 regation was blocked using a monoclonal anti-platelet activating factor receptor (PafR) antibody and

37 er of melanoma metastasis, via activation of platelet-activating factor receptor (PAFR) and cAMP-resp

38 dditional recognition system mediated by the platelet-activating factor receptor (PAFr) and directed

39 e hypothesis that influenza up-regulates the platelet-activating factor receptor (PAFr) and thereby p

40 Inhibitors of platelet-activating factor receptor (PAFR) blocked LTA-

41 We have previously shown that the Platelet-Activating Factor Receptor (PAFR) engagement in

42 The platelet-activating factor receptor (PAFr) has been sugg

43 hibitors identified a prominent role for the platelet-activating factor receptor (PAFr) in hypoxia-as

44 Platelet-activating factor receptor (PAFR) is a G protei

45 Chinese hamster ovary cells, the M1AChR and platelet-activating factor receptor (PAFR) mediate MAPK

46 Platelet-activating factor receptor (PAFr) mediates pneu

47 f synaptic activity in a manner dependent on platelet-activating factor receptor (PAFR) signaling.

48 polymeric immunoglobulin receptor (pIgR) and platelet-activating factor receptor (PAFr) to attach and

49 iciency in interleukin 1alpha (IL-1alpha) or platelet-activating factor receptor (PAFR), an important

50 of A. baumannii binds to A549 cells through platelet-activating factor receptor (PAFR), resulting in

51 Moreover, expression of platelet-activating factor receptor (PAFR), which is kno

52 nvolved in immune responses include CD36 and platelet-activating factor receptor (PAFR).

53 r airway cells is mediated by host-expressed platelet-activating factor receptor (PAFR).

54 ent studies used model systems consisting of platelet-activating factor receptor-positive and -negati

55 3T cDNA exhibited a pronounced impairment in platelet-activating factor receptor-stimulated inositol

56 The ability of the epidermal platelet-activating factor receptors to modulate oxidant

57 Bacterial lipoteichoic acid activates the platelet-activating factor receptor, which is G protein-